On-treatment markers as predictors to guide anti-EGFR MoAb treatment in metastatic colorectal cancer: a systematic review with meta-analysis

被引:0
作者
Jing Hu
Zhen Zhang
Rui Zheng
Lei Cheng
Mi Yang
Li Li
Baorui Liu
Xiaoping Qian
机构
[1] Nanjing University of Traditional Chinese Medicine,Comprehensive Cancer Center, Nanjing Drum Tower Hospital Clinical College of Traditional Chinese and Western Medicine
[2] China Pharmaceutical University,College of Basic Medicine and Clinical Pharmacy
[3] Clinical Cancer Institute of Nanjing University,Comprehensive Cancer Center of Drum Tower Hospital, Medical School of Nanjing University
来源
Cancer Chemotherapy and Pharmacology | 2017年 / 79卷
关键词
Colorectal cancer; On-treatment markers; Skin toxicity; Early tumor shrinkage; Cetuximab; Panitumumab;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:275 / 285
页数:10
相关论文
共 132 条
[1]  
Jemal A(2011)Global cancer statistics CA 61 69-90
[2]  
Bray F(2014)Managing advanced colorectal cancer: have we reached the PEAK with current therapies? J Clin Oncol 32 2200-2202
[3]  
Center MM(2013)Controversies in antiepidermal growth factor receptor therapy in metastatic colorectal cancer Cancer 119 1941-1950
[4]  
Wolpin BM(2014)Anti-EGFR MoAb treatment in colorectal cancer: limitations, controversies, and contradictories Cancer Chemother Pharmacol 74 1-13
[5]  
Bass AJ(2009)Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab Ann Oncol 20 227-230
[6]  
Woo J(2013)Prognostic value of cetuximab-related skin toxicity in metastatic colorectal cancer patients and its correlation with parameters of the epidermal growth factor receptor signal transduction pathway: results from a randomized trial of the GERMAN AIO CRC Study Group Int J Cancer 132 236-245
[7]  
Palmisiano N(2009)Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy Cancer 115 1544-1554
[8]  
Tester W(2013)Use of early tumor shrinkage to predict long-term outcome in metastatic colorectal cancer treated with cetuximab J Clin Oncol 31 3764-3775
[9]  
Cheng L(2012)The initial change in tumor size predicts response and survival in patients with metastatic colorectal cancer treated with combination chemotherapy Ann Oncol 23 948-954
[10]  
Ren W(1996)Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17 1-12